Novo Nordisk es una compañía sanitaria global líder, fundada en 1923 con sede en Dinamarca. Nuestro propósito es impulsar el cambio para combatir la diabetes y otras enfermedades crónicas graves, como la obesidad y los desórdenes sanguíneos y endocrinos raros. Lo hacemos liderando avances científicos, expandiendo el acceso a nuestros medicamentos y trabajando para prevenir y finalmente curar las enfermedades. Novo Nordisk da empleo a unas 43.500 personas en 80 países y comercializa sus productos en unos 170 países. Para más información, visite novonordisk.com [http://www.novonordisk.com/], Facebook [http://www.facebook.com/novonordisk], Twitter [http://www.twitter.com/novonordisk], LinkedIn [http://www.linkedin.com/company/novo-nordisk], YouTube [http://www.youtube.com/novonordisk].
Más información
Medios: Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com Inversores: Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com Ann Sndermlle Rendbk +45 3075 2253 arnd@novonordisk.com Mark Joseph Root +45 3079 4211 mjhr@novonordisk.com
_______________________
*NCT03922750: A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
Referencias
1. Bajaj HS, Isendahl J, Gowda A, et al. Efficacy and Safety of Switching to Insulin Icodec, a Once-Weekly Basal Insulin, vs Insulin Glargine U100 in Patients with T2D Inadequately Controlled on OADs and Basal Insulin. Abstract 657. Presented at the 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020, The impact of new basal insulins, 12:00-13:00 CEST el 22 de septiembre de 2020.
2. ClinicalTrials.gov. A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03922750 [https://clinicaltrials.gov/ct2/show/NCT03922750]. Consultado: Septiembre de 2020.
3. Lingvay I, Koefoed MM, Stachlewska K, et al. Effect of Three Different Titration Algorithms of Insulin Icodec vs Insulin Glargine U100 on Time in Range in Patients with T2D Inadequately Controlled on OADs. Abstract 658. Presented at the virtual 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020, The impact of new basal insulins, 12:00-13:00 CEST el 22 de septiembre de 2020.
4. ClinicalTrials.gov. A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03951805 [https://clinicaltrials.gov/ct2/show/NCT03951805]. Consultado: Septiembre de 2020.
5. Rosenstock J, Kjrsgaard MIS, Mller DV, et al. Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs Once-Daily Insulin Glargine U100 in Insulin Nave Patients with T2D Inadequately Controlled on OADs. Abstract 56. Presented at the virtual 56th European Association for the Study of Diabetes Annual Meeting 2020, Developing better insulins, 14:45-15:00 CEST el 22 de septiembre de 2020.
6. Rosenstock J, Bajaj HS, Janez A, et al. Once-Weekly Insulin for Type 2 Diabetes Without Previous Insulin Treatment. New England Journal of Medicine. 2020; Published online ahead of print; DOI: 10.1056/NEJMoa2022474. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2022474 [https://www.nejm.org/doi/full/10.1056/NEJMoa2022474].
7. Rosenstock J, Kjrsgaard MIS, Mller DV, et al. Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs Once-Daily Insulin Glargine U100 in Insulin Nave Patients with T2D Inadequately Controlled on OADs. Abstract 238-OR. Presented at the 80th Scientific Sessions of the Virtual American Diabetes Association Annual Meeting, Insulin Therapies, 18:15-18:30 CDT el 14 de junio de 2020.
8. Hvelmann U, Brndsted L, Kristensen NR. et al. Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Abstract 237-OR. Presented at the 80th Scientific Sessions of the American Diabetes Association, Insulin Therapies, 18:00-18:15 CDT el 14 de junio de 2020.
9. Nishimura E, Kjeldsen T, Hubálek F, et al. Molecular and Biological Properties of Insulin Icodec, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing. Abstract 236-OR. 80th Scientific Sessions of the American Diabetes Association; Insulin Therapies, 17:45-18:00 CDT el 14 de junio de 2020.
Sitio Web: http://novonordisk.com/